[1] LO DICO R,FARON M,YONEMURA Y,et al.Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer:results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International(PSOGI)[J].Eur J Surg Oncol,2021,47(1):89-100.
[2] 蔡宇,罗利琼.靶向谷氨酰胺和PD1抑制剂在肝癌中的研究进展[J].现代医学,2022,50(8):1077-1081.
[3] MAUCORT-BOULCH D,DE MARTEL C,FRANCESCHI S,et al.Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide[J].Int J Cancer,2018,142(12):2471-2477.
[4] ABDEL-RAHMAN O.A real-world,population-based study for the outcomes of patients with metastatic colorectal cancer to the liver with distant lymph node metastases treated with metastasectomy[J].J Comp Eff Res,2022,11(4):243-250.
[5] VALERY P C,LAVERSANNE M,CLARK P J,et al.Projections of primary liver cancer to 2030 in 30 countries worldwide[J].Hepatology,2018,67(2):600-611.
[6] SAKUDA T,KUBO T,JOHAN M P,et al.Development of an oncolytic recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA[J].Anticancer Res,2020,40(11):6319-6325.
[7] NAKATAKE M,KUWANO N,KAITSURUMARU E,et al.Fusogenic oncolytic vaccinia virus enhances systemic antitumor immune response by modulating the tumor microenvironment[J].Mol Ther,2021,29(5):1782-1793.
[8] RIDER P J F,UCHE I K,SWEENY L,et al.Anti-viral immunity in the tumor microenvironment:implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy[J].Curr Clin Microbiol Rep,2019,6(4):193-199.
[9] 刘东涛,马俊文,丁波,等.表达CD40配体的溶瘤痘苗病毒(CD40L-VV)抑制结直肠癌细胞生长并增强荷瘤小鼠T细胞抗肿瘤活性[J].细胞与分子免疫学杂志,2021,37(7):602-607.
[10] JIN J,WANG R,YANG J,et al.Bispecific antibody expressed by an oncolytic herpes simplex virus type 2 can transform heterologous T cells into uniform tumor killer cells[J].Hum Gene Ther,2022,33(11-12):649-663.
[11] BEUG S T,PICHETTE S J,ST-JEAN M,et al.Combination of IAP antagonists and TNF-alpha-armed oncolytic viruses induce tumor vascular shutdown and tumor regression[J].Mol Ther Oncolytics,2018,10:28-39.
[12] ALAJEZ N M,MOCANU J D,SHI W,et al.Efficacy of systemically administered mutant vesicular stomatitis virus(VSVDelta51) combined with radiation for nasopharyngeal carcinoma[J].Clin Cancer Res,2008,14(15):4891-4897.
[13] ALAJEZ N M,MOCANU J D,KRUSHEL T,et al.Enhanced vesicular stomatitis virus(VSVDelta51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent[J].Cancer Cell Int,2012,12(1):27.
[14] LINK A,VOGT T K,FAVRE S,et al.Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells[J].Nat Immunol,2007,8(11):1255-1265.
[15] JIANG J,WANG W,XIANG W,et al.The phosphoinositide 3-kinase inhibitor ZSTK474 increases the susceptibility of osteosarcoma cells to oncolytic vesicular stomatitis virus VSVDelta51 via aggravating endoplasmic reticulum stress[J].Bioengineered,2021,12(2):11847-11857.
[16] LUTHER S A,BIDGOL A,HARGREAVES D C,et al.Differing activities of homeostatic chemokines CCL19,CCL21,and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis[J].J Immunol,2002,169(1):424-433.
[17] ADACHI K,KANO Y,NAGAI T,et al.IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J].Nat Biotechnol,2018,36(4):346-351.
[18] ZHANG Y,LI B,BAI Q,et al.The lncRNA Snhg1-Vps13D vesicle trafficking system promotes memory CD8 T cell establishment via regulating the dual effects of IL-7 signaling[J].Signal Transduct Target Ther,2021,6(1):126.
[19] WEI J,ISHIZUKA J J.Going viral:HBV-specific CD8(+) tissue-resident memory T cells propagate anti-tumor immunity[J].Immunity,2021,54(8):1630-1632.
[20] ATASHEVA S,SHAYAKHMETOV D M.Oncolytic viruses for systemic administration:engineering a whole different animal[J].Mol Ther,2021,29(3):904-907. |